-
1.
IgG Antibodies & IBD/IBS - NED Infobite
Infobite 27_April 2022. Summaries of key research on IgG antibodies and inflammatory bowel disease and irritable bowel syndrome
2024
Abstract
Elimination diets based on IgG-dependent food sensitivity are showing promise for conditions such as IBS, Crohn's disease and migraines. This NED Infobite highlights a number of clinical trials where IgG food sensitivity testing is put to the test. BANT's scientific NED InfoBites are designed to provide key elements of the latest research using plain language. They provide quick overviews on particular health issues and nutrition topics for a speedy introduction to the science. Visually attractive and easily shareable with clients and social media followers.
-
2.
Which Probiotics are best for IBD?
OptiBac Probiotics specialise entirely in probiotics. One of their core values is encouraging people to take health into their own hands in a responsible manner. Training and education is a cornerstone of this, and with their expertise, they hope to help raise awareness of probiotics and their potential to help change lives.
2024
Abstract
It is thought that imbalances in gut flora may contribute to the pathogenesis of Inflammatory Bowel Disease (IBD) suggesting probiotics may be a useful intervention. This blog post reviews the evidence for using specific strains of probiotics (namely E.Coli and Saccharomyces boulardii) in both Ulcerative Colitis (UC) and Crohn’s Disease. Additional research is needed in this field although advances in research could show promise for the utilisation of probiotics in the future.
-
3.
Inflammatory Bowel Disease with Clemmie Oliver
Nicola Moore is a seasoned nutritional therapist with a forward-thinking approach in the nutrition and lifestyle medicine sector. In her podcast, Healthily, she chats with colleagues and friends from her multiple years in the health industry to find out what it means to them to live healthily.
2024
Abstract
Nicola chats to Clemmie Oliver, who set up The Nutrition and Lifestyle Medicine Clinic in 2018 having suffered with IBD herself, to improve the quality of life of other people with Inflammatory Bowel Disease (IBD). They discuss the differences between Crohn’s and Ulcerative Colitis (UC) and also how to differentiate with Irritable Bowel Syndrome (IBS). A large part of the discussion encompasses dietary interventions for IBD, and how diet plays a part both during relapse and remission. They also touch upon supplements and when it might not be appropriate to recommend probiotics.
-
4.
The NED Journal - Microbiome in IBS, IBD and Health
Issue 3_April 2024 Gut Health. Peer-reviewed expert reviews and clinical insights from the Nutrition Evidence Editorial Board and Expert Review Panel
2024
Abstract
This 3rd edition of the NED Journal shines a light on the many and varied ways the microbiome interacts with human health, from different disease states and multiple life stages. In includes sections on the common diagnosis of irritable bowel syndrome, as well as the challenging autoimmune inflammatory bowel diseases. This NED Journal transforms the science to enable individualised science-based clinical decision making, with 23 peer-reviewed expert reviews. The NED Journal supports BANT members and other integrative and personalised medicine practitioners with their evidence-based practice.
-
5.
The Association between Total Protein, Animal Protein, and Animal Protein Sources with Risk of Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis of Cohort Studies.
Talebi, S, Zeraattalab-Motlagh, S, Rahimlou, M, Naeini, F, Ranjbar, M, Talebi, A, Mohammadi, H
Advances in nutrition (Bethesda, Md.). 2023;14(4):752-761
-
-
-
-
Free full text
-
Plain language summary
Inflammatory bowel diseases (IBD), like Crohn's disease (CD) and ulcerative colitis (UC), are characterised by recurrent inflammation of the intestinal tract. There has been a global rise in these conditions, which presents a significant economic burden and impacts the quality of life of the individual. Factors such as dysregulated immune response, genetic predisposition, gut microbiome, and environmental elements are believed to influence IBD development, with growing attention on the role of diets. Despite extensive research, the impact of dietary protein on IBD remains inconclusive. To address this gap a dose-dependent meta-analysis was conducted to explore the relationship between total protein, animal protein, and their sources with recurrent inflammation in IBD. The study included 11 prospective cohort studies spanning from 2010 to 2022, comprising 8,067 cases and 4,302,554 participants. The analysis showed no significant association between most dietary protein sources and IBD incidences. However, an increase in total meat intake was correlated with a higher risk of IBD, while protein consumption from dairy products appeared to be protective against IBD development, with some ethnic variations noted. The authors also discussed potential mechanisms, including the impact on the microbiome and the presence of compounds with adverse health effects. They emphasised the need for more intervention trials to validate these findings and shed further light on the relationship between dietary protein and IBD.
Expert Review
Conflicts of interest:
None
Take Home Message:
- According to the researchers, the effect of the high consumption of meat in increasing the risk of IBD is not related to the type of protein contained in it but could be due to cooking meat at high temperatures
- Other studies have reported that the consumption of animal proteins, especially processed and red meat, increases the risk of IBD
- Other studies related to dairy intake have been contradictory. There is also evidence reported of a positive effect from dairy exclusion in IBD patients.
- Further research is required to corroborate the findings of this systematic review.
Evidence Category:
-
X
A: Meta-analyses, position-stands, randomized-controlled trials (RCTs)
-
B: Systematic reviews including RCTs of limited number
-
C: Non-randomized trials, observational studies, narrative reviews
-
D: Case-reports, evidence-based clinical findings
-
E: Opinion piece, other
Summary Review:
Introduction
The authors conducted a dose-dependent meta-analysis of prospective cohort studies which examined the relation between total protein, animal protein, and animal protein sources with inflammatory bowel disease (IBD) in adults because the prevalence and incidence of IBD have exceeded globally.
Methods
Cochrane methodology was undertaken for the systematic review. Data from 11 prospective cohort studies with 8067 cases and 4,302,554 participants was extracted by 2 independent investigators. Evaluation of the quality and possible biases of included studies was performed. Risk ratios (RR) with 95% confidence intervals were chosen as the effect estimate. Various subgroup analyses were undertaken as well as metaregression analyses.
Results
- Seven cohort studies (7232 cases, 1,097,040 participants) were included in the analysis of dairy intake. Higher intakes of dairy was associated with a lower risk of IBD (RR: 0.81; 95% CI: 0.72, 0.90; n = 7)
- Consumption of protein from dairy products was found to be protective against IBD risk (RR = 0.77; 95% CI: 0.68, 0.88)
- Three prospective cohort studies with 1214 cases of IBD among a total of 535,738 subjects were included in the total meat analyses. Higher dietary total meat intake was not associated with the risk of IBD (RR: 1.24; 95% CI: 0.90, 1.70; n = 4)
- A positive linear association was found between total meat intake and risk of IBD. 100 g/d increment in dietary total meat consumption was associated with a 38% greater risk of IBD (RR: 1.38, 95% CI: 1.13, 1.68)
- Three prospective cohorts, among 492,497 participants and 4025 cases were included in the analysis of egg consumption. No association was found between egg consumption and IBD risk (RR: 0.92; 95% CI: 0.81, 1.04; n = 4).
Conclusion
The findings indicated no notable correlation between the intake of the majority of dietary protein sources and the incidence of IBD. IBD risk only escalated with higher total meat consumption, while the intake of protein from dairy products emerged as a protective factor against the risk of IBD.
Clinical practice applications:
- Dairy product consumption may be protective against IBD. However the studies included with statistically significant results did not control for alcohol intake and other confounding factors. The type of dairy product consumed, as well as a personalised approach, should be considered
- This study did not find any association between red or processed meat consumption and risk of IBD. However the subgroup analysis did find a significant association between red meat intake and IBD risk. This difference in results may be caused by differences in cooking methods, genetic factors, amount of meat consumption, confounding factors, and other environmental factors
- Total meat intake, as well as type of meat intake, and how meat is cooked, should be reviewed in clients with IBD, Crohn's Disease and Ulcerative Colitis.
Considerations for future research:
- Intervention studies would need to be conducted to corroborate the findings of this systematic review
- Future research should fully consider cofounding factors, such as alcohol intake and body mass index (BMI)
- Future studies should further consider types of protein as well as dose and cooking implications.
Abstract
We aimed to conduct this dose-dependent meta-analysis to examine the relation between total protein, animal protein, and its sources with inflammatory bowel disease (IBD). We searched databases, comprising PubMed/Medline, Web of Science (ISI), Embase, and Google Scholar, for the published studies up to 28 March 2023. Prospective cohort study designs that investigated associations between dietary intake of various animal protein sources and with risk of IBD in the general population were identified. Eleven prospective cohort studies with 4,302,554 participants and 8067 cases were considered eligible. Findings indicated that higher intake of dairy was significantly associated with a lower risk of IBD (relative risk [RR]: 0.81; 95% confidence interval [CI]: 0.72, 0.90), Crohn disease (RR: 0.69; 95% CI: 0.56, 0.86), and ulcerative colitis (RR: 0.84; 95% CI: 0.75, 0.94). There was no association between different sources of animal protein and the risk of IBD. The dose-response analysis suggested that each 100 g/d increment in dietary total meat consumption was associated with a 38% greater risk of IBD. Moreover, a positive linear association was found between total meat intake and risk of IBD (Pnonlinearity = 0.522, Pdose-response = 0.005). Overall, among the dietary sources of protein, the risk of IBD increased only with increasing total meat intake, and the consumption of protein from dairy products was found to be a protective factor against the IBD risk. This trial was registered at PROSPERO as CRD42023397719.
-
6.
Diet as an Optional Treatment in Adults With Inflammatory Bowel Disease: A Systematic Review of the Literature.
Jaramillo, AP, Abaza, A, Sid Idris, F, Anis, H, Vahora, I, Moparthi, KP, Al Rushaidi, MT, Muddam, M, Obajeun, OA
Cureus. 2023;15(7):e42057
-
-
-
-
Free full text
Plain language summary
Crohn's disease (CD) and ulcerative colitis (UC) are linked with significant morbidity and higher healthcare costs. The current model of CD pathogenesis implies that environmental variables and the gut microbiota interact in those who are genetically predisposed to the condition. The aim of this study was to investigate a treatment based on the diet of IBD patients. This study was a systematic review of nine studies. Results showed that following a diet that reduces inflammation may prevent its recurrence in UC patients in clinical remission. In fact, there were significant systemic changes in the intestinal microbiota of anti-inflammatory diet patients. Authors concluded that a four-week FODMAP diet combined with professional counseling and regular follow-up will be helpful in the therapy of persistent gastrointestinal symptoms in quiescent IBD, although care should be used in the long run.
Expert Review
Conflicts of interest:
None
Take Home Message:
Whilst concise, this limited review highlights the current lack of evidence supporting stand alone dietary strategies in preventing relapse for IBD patients. At the very least an anti-inflammatory diet should ideally be implemented alongside specific medical care and counselling to minimise risk of disease relapses.
Evidence Category:
-
A: Meta-analyses, position-stands, randomized-controlled trials (RCTs)
-
X
B: Systematic reviews including RCTs of limited number
-
C: Non-randomized trials, observational studies, narrative reviews
-
D: Case-reports, evidence-based clinical findings
-
E: Opinion piece, other
Summary Review:
Introduction
This systematic review evaluated the efficacy of diet as a preventative therapeutic treatment for Inflammatory Bowel Disease (IBD).
Methods
A total of 9 studies (published in the last 5 years) were chosen. The articles included 6 randomised controlled trials (RCT), one systematic literature review (SLR) and two SLR and meta-analysis. The authors used the Assessment Systematic Reviews (AMSTAR) approach and an unspecified Cochrane Risk of Bias assessment tool.
Results
(The following refers to the original RCT articles as the review article data was sparse).
- A 6-month, open-label, randomised, placebo-controlled trial of 53 adult Ulcerative Colitis (UC) patients compared response to an Anti-inflammatory Diet (AID) with Canada’s Food Guide (CFG). The outcome showed that the faecal calprotectin value (<150 µg/g at the endpoint) was significantly higher in the AID group (69.2 vs. 37.0%, p = 0.02) (Keshteli et al., 2022).
- The Specific Carbohydrate Diet (SCD) was not superior to the Mediterranean Diet (MD) in terms of achieved symptomatic remission at 6 weeks (SCD 46.5%, MD 43.5%; p = .77) (Lewis et al., 2022).
- A single-blind, 4-week trial concluded significant relief from gut symptoms was achieved when comparing a low FODMAP diet (14/27, 52% of positive patient feedback) to a control diet (4/25, 16%, p=.007) (Cox et al., 2020).
- A 7-day trial of 28 volunteers compared individualised food-based diet (CD-TREAT), with similar composition to Exclusive Enteral Nutrition (EEN) and found a change in relative abundance in faecal microbiome genera of 58 (49.3%) and 38 (32.3%) following both feeding practices respectively (Svolos et al., 2019).
- Substantial reduction in red and processed meat was not significant in reducing time to symptomatic relapse in Crohn’s Disease (CD) patients when comparing 115 high red meat consumers with 87 low red meat CD patients (p = 0.61 any relapse and p = 0.50 for moderate to severe relapse) (Aldenberg et al., 2019).
Conclusion
An anti-inflammatory diet may prolong clinical remission for UC patients. CD patients, with mild to severe symptoms, may tolerate both the MD and SCD equally well. The authors advise a low FODMAP diet for a 4-week period combined with professional counselling and regular follow-up sessions to delay flare-up episodes. However the findings were based on a very limited number of scientific material that requires extensive further assessment prior to deriving any firm conclusions.
Clinical practice applications:
- In order to delay relapse in IBD it is imperative that foods that support anti-inflammatory mechanisms are incorporated and maintained
- Whilst limited, the papers reviewed highlight potential for an initial low FODMAP diet followed by a longer term MD or SCD combined with constant monitoring
- From one study, red meat consumption did not appear to exacerbate symptoms.
Considerations for future research:
- Future studies need to include larger cohorts to ascertain the efficacy of dietary interventions as a stand alone treatment option for IBD
- Longer periods of intervention are needed to confirm dietary intervention efficacy and safety in this population.
Abstract
While the exact cause of IBD is unknown, there are a number of factors that are thought to contribute to its development, including environmental and genetic factors. While exclusive enteral nutrition (EEN) is a promising therapy for Crohn's disease (CD), it is not yet considered a first-line treatment. Additionally, the efficacy of EEN compared to corticosteroid treatment is still being investigated. EEN is suggested as a first-line therapy by which guidelines and in which age groups, as it may differ in pediatric and adult recommendations. Another finding was that dietary changes involving an increase in anti-inflammatory foods and decreased intake of foods high in inflammatory compounds are linked to a beneficial outcome both metabolically and microbiologically in patients with ulcerative colitis (UC) in remission. For relevant medical literature, we examined PubMed/Medline, the Cochrane Library, and Google Scholar as examples of medical databases. The articles were identified, evaluated, and eligibility applied, and nine publications were found. The finished articles investigated the role of several diet alternatives for patients with IBD. Some others have shown that following a normal low-fat diet may be effective in reducing the occurrence of subclinical colitis. The EEN and partial enteral nutrition (PEN) indicated no significant differences between both regimens, but both had good outcomes during active IBD. Other strict diets, such as the specific carbohydrate diet (SCD) versus the Mediterranean diet (MD), demonstrate excellent outcomes in patients with IBD. Fermentable oligosaccharides, disaccharides, monosaccharides, and polyols (FODMAP) dietary counseling improves gastrointestinal symptoms and quality of life in IBD patients. Based on the above, we concluded that more studies determining which component of the diet is not clear (proteins, carbs balanced) or diet types are required to establish a particular diet employed as a treatment intervention in these individuals.
-
7.
The Role of Genetically Engineered Probiotics for Treatment of Inflammatory Bowel Disease: A Systematic Review.
Zhang, T, Zhang, J, Duan, L
Nutrients. 2023;15(7)
-
-
-
-
Free full text
Plain language summary
Inflammatory bowel disease (IBD), largely classified as Crohn’s disease (CD) or ulcerative colitis (UC), is a chronic intestinal inflammatory disorder mediated by genetic, immune, microbial, and environmental factors. The aim of this study was to summarise the efficacy of different genetically modified probiotics compared to wild-type probiotics in the treatment of IBD in animal models and patients and to investigate the specific effects and main mechanisms involved. This study was a systematic review of forty-five preclinical studies and one clinical study. Results showed a protective effect of genetically modified organisms (gm) probiotics in colitis. Several protective mechanisms have been identified: reduction of the pro- to anti-inflammatory cytokine ratio in colonic tissue and plasma, modulation of the activity of oxidative stress in the colon, improvement of intestinal barrier integrity, modulation of the diversity and composition of gut microbiota, and production of favourable metabolites, including short-chain fatty acids, by beneficial bacteria. Authors concluded that gm probiotics are more effective and safer than wild-type probiotics, to facilitate clinical translation.
Expert Review
Conflicts of interest:
None
Take Home Message:
Conclusions of this review were largely based on mouse models and although treatment using probiotics is generally considered safe in humans, with only minor side-effects (flatulence), practitioners need to be aware that in an IBD population the use of GM formulations might not be completely without risk.
Evidence Category:
-
A: Meta-analyses, position-stands, randomized-controlled trials (RCTs)
-
X
B: Systematic reviews including RCTs of limited number
-
C: Non-randomized trials, observational studies, narrative reviews
-
D: Case-reports, evidence-based clinical findings
-
E: Opinion piece, other
Summary Review:
Introduction
This paper summarises the efficacy of specific genetically modified (GM) probiotic formulations for Inflammatory Bowel Disease (IBD) when compared to wild type probiotics. The aim was to ascertain what specific effects and mechanisms such probiotics have on IBD symptomatology.
Methods
- A total of 46 published articles were included; 45 mouse experimental models (induced acute or chronic colitis) (n=15-130) and 1 human IBD population clinical trial (n=10)
- The effect of GM probiotics were compared to placebo and wild-type probiotics in trials including preclinical studies, randomised controlled trials and cohort studies
- Animals received probiotics via gastric gavage (105 - 4 x 1012 CFU) for 3-6 weeks
- The human placebo-uncontrolled trial lasted 7 days and patients received 10 GM capsules of L.lactis (1 x 1010 CFU) twice daily.
Results
- GM probiotics that secrete immunoregulatory cytokines such as IL-10 appear to reduce intestinal damage
- The human trial using GM L.lactis resulted in 5 patients who went into complete clinical remission (CDAI, <150) with 3 patients exhibiting a clinical response (decrease in CDAI, >70). with only minor adverse events (flatulence)
- However, human cytokines that promote intestinal barrier function and epithelial restitution were not enhanced with oral administration of probiotics
- Two studies concluded that GM L.lactis and S.boulardii, that secrete atrial natriuretic peptide, might be the most effective options in supporting colitis
- GM L.casei resulted in faster recovery from weight loss in acute colitis models
- Superoxide dismutase (SOD) producing GM L.fermentum increased SOD activity by almost eightfold compared to the wild type
- GM Lact. fermentum furthermore showed a higher survival rate and lower disease activity index (P <0·05) in colitis models
- GM L.lactis improved gut microbial composition and GM S.cerevisiae improved microbial diversity whilst reducing the Firmicutes to Bacteroides ratio
- GM E.coli significantly reduced weight loss, colon shortening plus lower disease activity and histological changes (P < 0.05).
Conclusion
Despite the heterogeneity of the trials, GM probiotics appear to play a notable part in ameliorating IBD symptomatology and disease severity when compared to wild-type probiotics. Human efficacy and potential adverse effects require more in-depth trials to ascertain safety and optimal dosages.
Clinical practice applications:
- Probiotics species used in the trials included S.thermophilus, E.coli, L.lactis, B.ovatus, S.boulardii, L.fermentum, B.longhum, L.casei, L.plantarum, and S.cerevisiae. Wild-types of some of these are already available to use in clinical practice
- Note that oral administration in the human trial showed no significant health outcome, therefore efficacy and safety need to be ascertained on an individual patient level
- Colonisation of beneficial bacteria in the gut of IBD patients might be difficult and any form of supplementation therefore needs to be closely monitored.
Considerations for future research:
- More evidence is needed to demonstrate that GM probiotic formulations result in significantly improved outcomes when compared to wild-types
- Future randomised placebo-controlled trials need to include larger cohorts to determine supplement efficacy
- Longer periods of intervention are needed to confirm efficacy, safety, and tolerance for both Crohn’s Disease and Colitis
- Optimal GM probiotic formulation, doses, and means of application need to be identified.
Abstract
BACKGROUND Many preclinical studies have demonstrated the effectiveness of genetically modified probiotics (gm probiotics) in animal models of inflammatory bowel disease (IBD). OBJECTIVE This systematic review was performed to investigate the role of gm probiotics in treating IBD and to clarify the involved mechanisms. METHODS PubMed, Web of Science, Cochrane Library, and Medline were searched from their inception to 18 September 2022 to identify preclinical and clinical studies exploring the efficacy of gm probiotics in IBD animal models or IBD patients. Two independent researchers extracted data from the included studies, and the data were pooled by the type of study; that is, preclinical or clinical. RESULTS Forty-five preclinical studies were included. In these studies, sodium dextran sulfate and trinitrobenzene sulfonic acid were used to induce colitis. Eleven probiotic species have been genetically modified to produce therapeutic substances, including IL-10, antimicrobial peptides, antioxidant enzymes, and short-chain fatty acids, with potential therapeutic properties against colitis. The results showed generally positive effects of gm probiotics in reducing disease activity and ameliorating intestinal damage in IBD models; however, the efficacy of gm probiotics compared to that of wild-type probiotics in many studies was unclear. The main mechanisms identified include modulation of the diversity and composition of the gut microbiota, production of regulatory metabolites by beneficial bacteria, reduction of the pro- to anti-inflammatory cytokine ratio in colonic tissue and plasma, modulation of oxidative stress activity in the colon, and improvement of intestinal barrier integrity. Moreover, only one clinical trial with 10 patients with Crohn's disease was included, which showed that L. lactis producing IL-10 was safe, and a decrease in disease activity was observed in these patients. CONCLUSIONS Gm probiotics have a certain efficacy in colitis models through several mechanisms. However, given the scarcity of clinical trials, it is important for researchers to pay more attention to gm probiotics that are more effective and safer than wild-type probiotics to facilitate further clinical translation.
-
8.
Physical Training and Healthy Diet Improved Bowel Symptoms, Quality of Life, and Fatigue in Children With Inflammatory Bowel Disease.
Scheffers, LE, Vos, IK, Utens, EMWJ, Dieleman, GC, Walet, S, Escher, JC, van den Berg, LEM
Journal of pediatric gastroenterology and nutrition. 2023;77(2):214-221
-
-
-
-
Free full text
-
Plain language summary
Inflammatory bowel disease (IBD), including Crohn disease and ulcerative colitis, are chronic inflammatory diseases of the gastrointestinal tract, characterised by periods of remission and relapse of symptoms. The aim of this study was to assess the effects of a tailored lifestyle intervention on physical fitness (maximal and submaximal exercise capacity, strength, and core stability), the patient-reported outcomes (quality of life, fatigue, and fear), clinical disease activity, and nutritional status. This study was a prospective single-centre randomised semi-crossover-controlled trial. Children were randomized into group A (start exercise) or group B (start control period). Results showed improved physical fitness, quality of life, and parent-reported fatigue. Additionally, a combination of lower clinical disease activity scores accompanied by fewer IBD symptoms suggests positive effects on intestinal inflammation. Authors concluded that based on the findings of their study, children and adolescents with IBD should be motivated and supported to acquire and maintain a healthy lifestyle.
Expert Review
Conflicts of interest:
None
Take Home Message:
- IBD is a chronic inflammatory disease of the gastrointestinal tract, characterised by periods of abdominal pain, severe diarrhoea, and fatigue
- This clinical trial suggests that a 12-week program of physical training plus personalised healthy dietary advice may improve physical fitness, quality of life, and fatigue in children with IBD.
Evidence Category:
-
A: Meta-analyses, position-stands, randomized-controlled trials (RCTs)
-
X
B: Systematic reviews including RCTs of limited number
-
C: Non-randomized trials, observational studies, narrative reviews
-
D: Case-reports, evidence-based clinical findings
-
E: Opinion piece, other
Summary Review:
Introduction
A randomised semi-crossover controlled trial was conducted to investigate the impact of a 12-week lifestyle program (3 physical training sessions per week plus personalised healthy dietary advice) in children with Inflammatory Bowel Disease (IBD).
Method
- Sixteen children with a median age of 15 [IQR: 12–16]) that were diagnosed with IBD (CD, UC, or IBD-unclassified) were randomized to group A (start exercise) or group B (start control period). Group A started the intervention immediately after the first assessment and did not have a control period. Group B started after a control period (this was planned to last for 6 weeks but due to the COVID-19 lockdown extended to 6 months)
- The lifestyle intervention lasted 12 weeks and consisted of 3 physiotherapist-supervised training sessions per week, lasting 60 minutes each. In addition, all participants received a recommended caloric intake per day based on measured rest energy expenditure and a brochure regarding healthy diet in children
- Endpoints were physical fitness (maximal and submaximal exercise capacity, strength, and core stability), patient-reported outcomes (quality of life, fatigue, and fears for exercise), clinical disease activity (faecal calprotectin and disease activity scores), and nutritional status (energy balance and body composition)
- A total of 15 out of 16 participants (93%) completed the program, one patient dropped out after one training session due to motivational problems.
Results
The primary findings of this study were as follows:
- While medical treatment remained unchanged, Paediatric Crohn's Disease Activity Index decreased versus the control period (15 [3–25] vs 2.5 [0–5], P = 0.012)
- The number of patients in clinical remission increased from 5 to 12 (P < 0.001), compared to the control period
- Quality of life (IMPACT-III) improved on 4 out of 6 domains and the total score (+13 points) versus the control period including a large improvement in bowel-related symptoms, P= 0.029)
- Fecal calprotectin decreased, but not compared to the control period, mainly due to relatively large intra-patient fluctuations (400 μg/g [57.1–1662.7] vs 128 μg/g [23.8–642.3], P = 0.016)
- Parents reported an improvement in the quality of life versus the control period on the child health questionnaire and total fatigue score (PedsQoL • Multidimensional Fatigue Scale) (+14 points, P = 0.048)
- Walking distance improved after the 12-week program, compared to the control period (P = 0.001).
Conclusion
This study revealed that a 12-week physical training program and personalised dietary advice improved bowel symptoms, quality of life, and fatigue in children with IBD.
Clinical practice applications:
- The mechanism behind the anti-inflammatory effects of exercise has not been clarified
- Multiple theories have been suggested in previously published studies such as a reduced release of adipokines due to less visceral fat, increased secretion of anti-inflammatory cytokines such as interleukin (IL)-6, and reduced transient stool time
- This clinical trial demonstrated that a 12-week program of physical training sessions plus personalised healthy dietary advice resulted in improved physical fitness, quality of life, and parent-reported fatigue.
Considerations for future research:
- A sample size calculation was not provided in the study report and it is therefore assumed that the sample size of 16 children in this trial was too small to draw a definite conclusion. A larger study over a longer period is therefore needed across diverse age and ethnic population groups to draw better conclusions
- This study did not measure mucosal inflammation before and after the intervention due to the invasive nature of the procedure. It would however be useful that future research investigate this to gain more insight into the effect of lifestyle interventions on IBD.
Abstract
OBJECTIVES Physical activity programs have been suggested as adjunctive therapy in adult inflammatory bowel disease (IBD) patients. We assessed the effects of a 12-week lifestyle intervention in children with IBD. METHODS This study was a randomized semi-crossover controlled trial, investigating a 12-week lifestyle program (3 physical training sessions per week plus personalized healthy dietary advice) in children with IBD. Endpoints were physical fitness (maximal and submaximal exercise capacity, strength, and core stability), patient-reported outcomes (quality of life, fatigue, and fears for exercise), clinical disease activity (fecal calprotectin and disease activity scores), and nutritional status (energy balance and body composition). Change in maximal exercise capacity (peak VO 2 ) was the primary endpoint; all others were secondary endpoints. RESULTS Fifteen patients (median age 15 [IQR: 12-16]) completed the program. At baseline, peak VO 2 was reduced (median 73.3% [58.8-100.9] of predicted). After the 12-week program, compared to the control period, peak VO 2 did not change significantly; exercise capacity measured by 6-minute walking test and core-stability did. While medical treatment remained unchanged, Pediatric Crohn's Disease Activity Index decreased significantly versus the control period (15 [3-25] vs 2.5 [0-5], P = 0.012), and fecal calprotectin also decreased significantly but not versus the control period. Quality of life (IMPACT-III) improved on 4 out of 6 domains and total score (+13 points) versus the control period. Parents-reported quality of life on the child health questionnaire and total fatigue score (PedsQoL Multidimensional Fatigue Scale) also improved significantly versus the control period. CONCLUSIONS A 12-week lifestyle intervention improved bowel symptoms, quality of life, and fatigue in pediatric IBD patients.
-
9.
Nutrition, Nutritional Status, Micronutrients Deficiency, and Disease Course of Inflammatory Bowel Disease.
Valvano, M, Capannolo, A, Cesaro, N, Stefanelli, G, Fabiani, S, Frassino, S, Monaco, S, Magistroni, M, Viscido, A, Latella, G
Nutrients. 2023;15(17)
-
-
-
-
Free full text
Plain language summary
Inflammatory Bowel Disease (IBD) are chronic inflammatory diseases, mediated by the immune system, which affect the gastrointestinal tract. The two main manifestations are Crohn’s Disease and ulcerative colitis. Patients with IBD often experience malnutrition, undernutrition, or overnutrition during their disease. This study aimed to evaluate the connection between nutrition, nutritional status (including undernutrition and overnutrition), micronutrient deficiency, and the disease course in adult IBD patients. This study was a systematic review of 227 articles. The findings of this review showed that addressing various nutritional aspects could lead to better symptom control, deeper remission, and an overall improvement in the quality of life for IBD patients. The authors concluded that optimising nutritional management plays a crucial role in managing IBD effectively. Understanding the impact of nutrition on disease course can guide targeted interventions for better patient outcomes.
Expert Review
Conflicts of interest:
None
Take Home Message:
- Dietary intervention to support optimal weight management, contain anti-inflammatory components, and specific micronutrient intake should be the basis of any treatment protocol.
- Vitamin C deficiency was noted in patients who under consume fruit and vegetables, had resection surgery, and disease progress and should therefore be addressed via diet and supplementation.
- Serum screening of iron, zinc, folate, vitamin A, B1, B12, C, and D is essential and supplementation based on those findings should be considered alongside specific dietary interventions that can be different for CD and UC patients.
- Comprehensive stool analysis should be considered to elicit any potential dysbiosis that may impact on nutrient absorption in a population that is at greater risk of sub-optimal nutritional status.
Evidence Category:
-
A: Meta-analyses, position-stands, randomized-controlled trials (RCTs)
-
X
B: Systematic reviews including RCTs of limited number
-
C: Non-randomized trials, observational studies, narrative reviews
-
D: Case-reports, evidence-based clinical findings
-
E: Opinion piece, other
Summary Review:
Introduction
The aim of this systematic review was to establish a clear connection between nutrition, malnutrition, and micronutrient deficiency pertaining to disease pathology of Inflammatory Bowel Disease (IBD).
Methods
Following a PubMed/MEDLINE and Scopus literature search, a total of 227 human IBD studies were reviewed.
Results
- High fibre diets protect against relapse.
- Overall exclusion diets had insufficient data. Positive outcomes noted by Sarbagili-Shabat et al. 2021 and Yanai et al., 2022.
- Sarcopenia in CD patients may result in a slight increase of disease pathophysiology.
- All studies showed that albumin plays a fundamental role in the disease course, response to drugs, surgery rates, and post-surgical complications.
- All studies showed anaemia appears to be associated with high severity of IBD, or higher risk of post-surgical complications.
- Obesity may worsen the effectiveness of IBD therapies and increase post-operative complications.
- Iron deficiency affects about 50% of IBD patients.
- Vitamin B12 deficiency is prevalent in 33% of CD patients (particularly patients who had an ileal resection longer than 20 cm) compared to 16% in UC patients.
- Folate deficiency is more common in UC patients.
- Low vitamin D levels in IBD patients increased odds of disease activity (OR:1.53, CI 1.32-1.77), mucosal inflammation (OR:1.30, CI 1.06-1.60), and future clinical relapse (OR:1.23, CI 1.03-1.47).
- Plasma vitamin A is significantly lower in active UC patients compared to controls (p = 0.0005). Note a significant association between vitamin A in CD patients and C-reactive protein (p = 0.03).
- Vitamin B1 supplementation (600-1800 mg/d) showed a mean reduction of 4.5 points (95% CI 2.6-6.2) in fatigue compared with a mean increase of 0.75 point (95% CI -1.3-2.8; p = 0.0003) after placebo (Bager et al., 2021).
- Oral zinc sulfate supplements (110 mg t.i.d.) significantly lowered intestinal permeability after 8 weeks (0.041 ± 0.003 versus 0.026 ± 0.005; p = 0.0028) (Sturniolo et al., 2001).
Conclusion
Specific dietary and micronutrient interventions could potentially alter IBD progress inclusive of nutritional status, delay of surgical intervention, earlier remission and improved quality of life.
Clinical practice applications:
- Optimal weight maintenance is important for IBD patients given the association with disease complications.
- Regular screening for nutritional status is essential based on the potential impact of nutrient deficiencies on disease outcome.
- Oral iron supplementation may be not well tolerated in IBS patients and intravenous supplementation should be considered depending on regular screening of iron status.
Considerations for future research:
Larger homogeneous studies and stronger evidence are needed to elicit specific protocols to induce remission and the effect on risk of surgical intervention in IBD patients.
Abstract
During the disease course, most Inflammatory Bowel Disease patients present a condition of malnutrition, undernutrition, or even overnutrition. These conditions are mainly due to suboptimal nutritional intake, alterations in nutrient requirements and metabolism, malabsorption, and excessive gastrointestinal losses. A suboptimal nutritional status and low micronutrient serum levels can have a negative impact on both induction and maintenance of remission and on the quality of life of Inflammatory Bowel Disease patients. We performed a systematic review including all the studies evaluating the connection between nutrition, nutrition status (including undernutrition and overnutrition), micronutrient deficiency, and both disease course and therapeutic response in Inflammatory Bowel Disease patients. This systematic review was performed using PubMed/MEDLINE and Scopus. Four main clinical settings concerning the effect of nutrition on disease course in adult Inflammatory Bowel Disease patients were analyzed (induction of remission, maintenance of remission, risk of surgery, post-operative recurrence, and surgery-related complications). Four authors independently reviewed abstracts and manuscripts for eligibility. 6077 articles were found; 762 duplicated studies were removed. Out of 412 full texts analyzed, 227 were included in the review. The evidence summarized in this review showed that many nutritional aspects could be potential targets to induce a better control of symptoms, a deeper remission, and overall improve the quality of life of Inflammatory Bowel Disease patients.
-
10.
Association of Vitamin D Level and Maternal Gut Microbiome during Pregnancy: Findings from a Randomized Controlled Trial of Antenatal Vitamin D Supplementation.
Aparicio, A, Gold, DR, Weiss, ST, Litonjua, AA, Lee-Sarwar, K, Liu, YY
Nutrients. 2023;15(9)
-
-
-
Free full text
Plain language summary
Changes in the gut bacteria during pregnancy and a lack of vitamin D can have negative health consequences for both mother and child. Vitamin D has important functions in the human body and is key in regulating immune and inflammatory responses. Evidence suggests that vitamin D helps to maintain gut wall integrity and regulate inflammatory mechanisms in response to bacteria. Gut bacteria themselves have immune regulatory functions, and unfavourable disruptions in the composition of the bacteria are associated with chronic inflammatory diseases. Evidence shows gut bacteria composition is influenced by Vitamin D. During pregnancy, a substantial alteration in gut bacteria composition occurs and as pregnancy advances, there's typically an increase in bacteria linked to inflammation. This study analysed the data from the Vitamin D Antenatal Asthma Reduction Trial (VDAART, 2014), a randomised placebo controlled trial which gathered information on the impact of vitamin D on various markers as well as gut microbiome composition in pregnant women. For the study all participants took a daily multivitamin with 400 IU Vitamin D during the third trimester of pregnancy, and were given either an additional 4000IU of Vitamin D or a placebo. Results were drawn from 114 participants and their baseline vitamin D levels in early pregnancy, its changes over the trial period, as well as gut bacteria composition. The vitamin D levels at the start aligned with expected outcomes and was strongly linked to race, income, and education level. The baseline vitamin D level in early pregnancy also showed a connection to certain gut microbiome composition. However, these bacterial constellations remained robust and did not show any changes in response to Vitamin D supplementation throughout pregnancy. During the trial, most participant's vitamin D levels increased, especially those in the 4400 IU treatment group. Interestingly, women whose vitamin D levels did not increase much throughout the trial displayed a higher abundance of a bacteria called Desulfovibrio. Desulfovibrio is associated with an increased incidence of respiratory and inflammatory bowel diseases and the authors suggested that increasing vitamin D during pregnancy might help prevent the growth of more unfavourable bacteria like Desulfovibrio. Further long-term research is needed to confirm this idea.
Abstract
Shifts in the maternal gut microbiome and vitamin D deficiency during pregnancy have been associated, separately, with health problems for both the mother and the child. Yet, they have rarely been studied simultaneously. Here, we analyzed the gut microbiome (from stool samples obtained in late pregnancy) and vitamin D level (from blood samples obtained both in early and late pregnancy) data of pregnant women in the Vitamin D Antenatal Asthma Reduction Trial (VDAART), a randomized controlled trial of vitamin D supplementation during pregnancy, to investigate the association of vitamin D status on the pregnant women's microbiome. To find associations, we ran linear regressions on alpha diversity measures, PERMANOVA tests on beta diversity distances, and used the ANCOM-BC and Maaslin2 algorithms to find differentially abundant taxa. Analyses were deemed significant using a cut-off p-value of 0.05. We found that gut microbiome composition is associated with the vitamin D level in early pregnancy (baseline), the maternal gut microbiome does not show a shift in response to vitamin D supplementation during pregnancy, and that the genus Desulfovibrio is enriched in women without a substantial increase in vitamin D level between the first and the third trimesters of pregnancy. We conclude that increasing the vitamin D level during pregnancy could be protective against the growth of sulfate-reducing bacteria such as Desulfovibrio, which has been associated with chronic intestinal inflammatory disorders. More in-depth investigations are needed to confirm this hypothesis.
